Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Hyperbaric oxygen therapy may be an efficacious therapy for IBD

A study published in the Alimentary Pharmacology & Therapeutics quantifies the safety and efficacy of hyperbaric oxygen therapy for Crohn's disease and ulcerative colitis.

News image

Hyperbaric oxygen therapy (HBOT) provides 100% oxygen under pressure, which increases tissue oxygen levels, relieves hypoxia and alters inflammatory pathways.

Although there is experience using HBOT in Crohn's disease and ulcerative colitis, the safety and overall efficacy of hyperbaric oxygen therapy in inflammatory bowel disease (IBD) is unknown.

Dr Corey Siegel and colleagues from the United Kingdom quantified the safety and efficacy of hyperbaric oxygen therapy for Crohn's disease and ulcerative colitis.

The rate of adverse events with hyperbaric oxygen therapy for IBD was compared to the expected rate of adverse events with hyperbaric oxygen therapy.

MEDLINE, EMBASE, Cochrane Collaboration and Web of Knowledge were systematically searched using the PRISMA standards for systematic reviews.

The research team identified 17 studies involving 613 patients.
In ulcerative colitis, the overall response rate to hyperbaric oxygen therapy was 100%
Alimentary Pharmacology & Therapeutics

The team noted that the overall response rate was 86%.

The overall response rate for perineal Crohn's disease was 88%.

Of the 40 ulcerative colitis patients with endoscopic follow-up reported, the overall response rate to hyperbaric oxygen therapy was 100%.

During the 8924 treatments, the team found a total of 9 adverse events, 6 of which were serious.

The team observed that the rate of adverse events with hyperbaric oxygen therapy in IBD is lower than that seen when utilizing HBOT for other indications.

The risk of bias across studies was high.

Dr Siegel and team conclude, "Hyperbaric oxygen therapy is a relatively safe and potentially efficacious treatment option for IBD patients."

"To understand the true benefit of hyperbaric oxygen therapy in IBD, well-controlled, blinded, randomized trials are needed for both Crohn's disease and ulcerative colitis."

Aliment Pharmacol Ther 2014: 39(11): 12661275
14 May 2014

Go to top of page Email this page Email this page to a colleague

 24 May 2016 
New therapies for NASH
 24 May 2016 
Fecal inflammatory markers in Crohn's
 24 May 2016 
Depression and IBD recurrence
 23 May 2016 
Cancer after colectomy in IBD
 23 May 2016 
Risk factors for peptic ulcer bleeding outcomes
 23 May 2016 
Liver transplantation for hepatocellular carcinoma
 20 May 2016 
Prognostic score for hepatic venous outflow obstruction
 20 May 2016 
Treatment for uncomplicated acute diverticulitis
 20 May 2016 
Biomarker for colorectal cancer diagnosis
 19 May 2016 
Probiotics and H. pylori eradication
 19 May 2016 
Impaired skeletal health in atrophic gastritis
 19 May 2016 
Predicting outcome in ulcerative colitis
 18 May 2016 
Erectile dysfunction in IBD
 18 May 2016 
Acute GERD and esophageal histologic changes
 18 May 2016 
Surgical fundoplication for GERD 
 17 May 2016 
Mucosal dysbiosis in Crohn's disease
 17 May 2016 
Vitamin D level and clinical status in IBD 
 17 May 2016 
Inpatient costs for IBD and acute pancreatitis
 16 May 2016 
Outcomes of postcolonoscopy colorectal cancers
 16 May 2016 
C. difficile in ulcerative colitis patients
 16 May 2016 
Therapy for Crohn's in a Medicaid population
 13 May 2016 
Parkinson's disease and IBD
 13 May 2016 
Non-traditional heart disease risk factors in NAFLD
 13 May 2016 
Inactivated oral cholera vaccine
 12 May 2016 
Gestational diabetes mellitus and NAFLD
 12 May 2016 
Impact of Crohn's in the USA
 12 May 2016 
Ozanimod induction and ulcerative colitis
 11 May 2016 
Anti-TNF discontinuation in IBD
 11 May 2016 
Age and disease presentation with Crohn's disease
 11 May 2016 
Prognosis after colorectal cancer resection
 10 May 2016 
Gluten-free diet in patients with IBS-diarrhea
 10 May 2016 
Noninvasive test for IBD
 10 May 2016 
Digital health for gastroenterology
 09 May 2016 
Diarrheal infections in adults
 09 May 2016 
Quality improvement initiative and readmission for cirrhosis
 09 May 2016 
Coffee or tea and the risk of Barrett's
 06 May 2016 
Recurrent pancreatitis after acute pancreatitis
 06 May 2016 
Risk factors in peptic ulcer bleeding
 06 May 2016 
Managing acute lower GI bleeding
 05 May 2016 
Chemoradiotherapy vs chemotherapy for pancreatic cancer
 05 May 2016 
Genetics in early-early-onset IBD
 05 May 2016 
Reductions in quality of screening colonoscopies
 04 May 2016 
Anti-TNF therapy for IBD
 04 May 2016 
Bismuth and H. pylori eradication
 04 May 2016 
Chromoendoscopy vs colonoscopy for dysplasia in colitis
 03 May 2016 
Vedolizumab for IBD
 03 May 2016 
PPIs and gut microbiota
 03 May 2016 
Surgery vs medical therapy for GERD
 02 May 2016 
Mycophenolate mofetil as first-line treatment of autoimmune hepatitis
 02 May 2016 
Genetic variant that increase NAFLD risk
 02 May 2016 
Resection of colorectal polyps
 29 April 2016 
HCV infection in Baby Boomers with Medicare
 29 April 2016 
Simvastatins and survival in cirrhosis
 29 April 2016 
Crohn's disease associated genes
 28 April 2016 
Birth outcomes in women with IBD receiving assisted reproduction
 28 April 2016 
Racial disparities in survival from colon cancer
 28 April 2016 
Diarrheal diseases in children
 27 April 2016 
Ultra-short celiac disease
 27 April 2016 
Celiac disease in adults
 27 April 2016 
Dust mite and human GI tract

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us